AstraZeneca and Moderna Therapeutics announce exclusive agreement to develop pioneering messenger RNA Therapeutics™ in cardiometabolic diseases and cancer

AstraZeneca and Moderna Therapeutics announce exclusive agreement to develop pioneering messenger RNA Therapeutics™ in cardiometabolic diseases and cancer

March 21, 2013

 

AstraZeneca today announced an exclusive agreement with Moderna Therapeutics to discover, develop and commercialise pioneering messenger RNA therapeutics™ for the treatment of serious cardiovascular, metabolic and renal diseases as well as cancer. Messenger RNA therapeutics™ are an entirely new treatment approach that enables the body to produce therapeutic protein in vivo, opening up new treatment options for a wide range of diseases that cannot be addressed today using existing technologies.

Flagship Ventures and Merck Research Labs Form Strategic Collaboration to Foster Early-Stage Life Sciences Innovation

Flagship Ventures and Merck Research Labs Form Strategic Collaboration to Foster Early-Stage Life Sciences Innovation

April 10, 2012

Initiative combines Merck’s drug development expertise with Flagship’s experience in building early stage companies

Denali Therapeutics Announces First Clinical Trial Application, Key Collaborations and $130M Series B

Denali Therapeutics Announces First Clinical Trial Application, Key Collaborations and $130M Series B

August 25, 2016

Denali Therapeutics Inc. (“Denali”) today announced several critical milestones in the company’s growth, including its first Clinical Trial Application (“CTA”) to initiate a Phase 1 trial, previously undisclosed collaborations and licensing deals, and a $130 million Series B equity financing. 

TransMedics, Inc.

Heartwarming Story: Developing a Better Way to Preserve Organs

Heartwarming Story: Developing a Better Way to Preserve Organs

August 14, 2016

 Read the story from Newsweek, featuring TransMedics Inc., here: http://www.newsweek.com/developing-better-way-preserve-organs-490058

Flagship Partner Dr. Jeremy Springhorn Panel Discussion Transcript

Flagship Partner Dr. Jeremy Springhorn Panel Discussion Transcript

August 12, 2016

In June 2016, Flagship partner Jeremy Springhorn spoke on a panel session, “Beyond the Cutting Edge: How to Enable Life Science Organizations Today for the Societal Challenges of Tomorrow,” at the BIO International Convention in San Francisco.

An edited transcript of his remarks, alongside other respected industry peers, has been published in the August 2016 issue of Life Science Leader.

Axcella to Present at Wedbush PacGrow Healthcare Conference

Axcella to Present at Wedbush PacGrow Healthcare Conference

August 9, 2016

CAMBRIDGE, Mass. – Axcella Health Inc., a biotechnology company pioneering transformative medicines for patients with conditions where disrupted amino acid biology plays a critical role, announced today that Robert Connelly, President and Chief Executive Officer, will present a company overview at the Wedbush PacGrow Healthcare Conference in New York, N.Y. The presentation will take place August 16, 2016, at 3:05 p.m. EDT.

About Axcella Health

Flagship Ventures Names Daniel McIntyre Partner

Flagship Ventures Names Daniel McIntyre Partner

June 29, 2016

Industry Veteran Assumes new position to lead strategic communication

CAMBRIDGE, Mass., June 29, 2016 -- Flagship Ventures today announced the appointment of Daniel McIntyre to the position of Partner, Strategic Communication. In this new role, he is responsible for communication for Flagship's growing organization as well as for its expanding ecosystem of internally generated start-up companies.

Evelo Biosciences and Epiva Biosciences Merge to Create the Leading Immuno-Microbiome Platform Company

Evelo Biosciences and Epiva Biosciences Merge to Create the Leading Immuno-Microbiome Platform Company

July 12, 2016

Company will focus on next generation immunotherapies for cancer, autoimmune and inflammatory diseases

Noubar Afeyan, Ph.D., Appointed Chairman; Executive Leadership Team Expanded

Dr. Michael Rosenblatt Joins Flagship Ventures as Chief Medical Officer

Dr. Michael Rosenblatt Joins Flagship Ventures as Chief Medical Officer

July 13, 2016

Cambridge, Mass., July 13, 2016 (PR Newswire) – Flagship Ventures today announced the appointment of industry veteran Michael Rosenblatt, M.D., to the new position of Chief Medical Officer. In this capacity, Dr. Rosenblatt will lead global clinical development and medical affairs for the organization.

Syros Pharmaceuticals Announces Pricing of Initial Public Offering

Syros Pharmaceuticals Announces Pricing of Initial Public Offering

June 29, 2016

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals today announced the pricing of its initial public offering of 4,000,000 shares of its common stock at a public offering price of $12.50 per share, before underwriting discounts and commissions. In addition, Syros has granted the underwriters a 30-day option to purchase up to 600,000 additional shares of common stock from Syros at the public offering price, less the underwriting discount and commissions, to cover over-allotments, if any. All of the shares are being offered by Syros Pharmaceuticals.